A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Last updated: March 7, 2025
Sponsor: Taiho Oncology, Inc.
Overall Status: Active - Recruiting

Phase

2

Condition

N/A

Treatment

TAS6417

Clinical Study ID

NCT05967689
TAS6417-201
2023-503865-48
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to evaluate the safety and efficacy of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and other mutations.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Written informed consent.

  2. ≥18 years of age (or meets the country's regulatory definition of legal adult age,whichever is greater.

  3. Pathologically confirmed, locally advanced or metastatic NSCLC meeting all thefollowing criteria: Cohort A participants:

  • Documented EGFR ex20ins status, as determined by local testing performed at aClinical Laboratory Improvement Amendments (CLIA) certified (United States [US]) or locally certified laboratory (outside the US).

  • Progressed on or after systemic therapy with an agent targeting ex20ins, eitheralone or in combination with standard platinum-based chemotherapy for thetreatment of advanced disease. Participants who discontinued previous treatmentdue to unacceptable toxicity are eligible. i. Permitted prior ex20ins therapies include: amivantamab, sunvozertinib (DZD9008), and BLU451. Other prior ex20ins--directed treatment may be discussedwith the Sponsor for eligibility assessment.

  • Participants with brain metastasis must be neurologically stable. Participantsmust have received central nervous system (CNS)-directed therapy and have noevidence of progression for at least 4 weeks after CNS-directed treatment, asascertained by clinical examination and brain imaging (magnetic resonanceimaging [MRI] or computed tomography [CT] scan) during the Screening Period.Additionally, they must be on a stable or decreasing dose of corticosteroidsand/or anti-convulsant medications for at least 2 weeks prior to the first doseof study treatment. Participants with a history of uncontrolled seizures or LMDare not eligible. Cohort B participants:

  • Documented EGFR ex20instatus, as determined by local testing performed at aCLIA-certified (US) or locally certified laboratory (outside the US).

  • Participants who have not received prior treatment for advanced or metastaticdisease and who are not appropriate candidates for first-line doubletplatinum-based chemotherapy based on Investigator judgment or has refusedfirst-line doublet platinum-based chemotherapy following discussion with theInvestigator. Prior adjuvant/neoadjuvant treatment for early-stage disease musthave been completed >6 months prior to the first dose of study treatment.

  • Participants with brain metastasis must be neurologically stable. Participantsmust have received CNS-directed therapy and have no evidence of progression forat least 4 weeks after CNS-directed treatment, as ascertained by clinicalexamination and brain imaging (MRI or CT scan) during the Screening Period, andthey must be on a stable or decreasing dose of corticosteroids and/oranti-convulsant medications for at least 2 weeks prior to the first dose ofstudy treatment. Participants with history of uncontrolled seizures or LMD arenot eligible. Cohort C participants:

  • Documented ex20ins or other uncommon single or compound EGFR non-ex20insstatus, as determined by local testing performed at a CLIA-certified (US) orlocally certified laboratory (outside the US).

  • Presence of brain metastasis(es) characterized as at least one of thefollowing:

  • Newly diagnosed and/or progressive brain metastasis(es) measurable byResponse Assessment in Neuro-oncology Brain Metastases (RANO-BM) criteriaand not subjected to CNS-directed therapy, AND/OR

  • LMD measurable or non-measurable by RANO-BM criteria and confirmed by apositive cerebrospinal fluid cytology, or unequivocal radiographic and/orclinical determination.

  • Participants may not require other immediate CNS-directed therapy or willlikely require other CNS directed anti-tumor therapy during the first cycle ofstudy treatment, as judged by the Investigator. Cohort D participants:

  • Documented other uncommon single or compound EGFR non-ex20ins status (excludingC797S), as determined by local testing performed at a CLIA certified (US) orlocally certified laboratory (outside the US). A list of eligible mutationswill be provided in a separate document.

  • Participants with brain metastasis must be neurologically stable. Participantsmust have received CNS-directed therapy and have no evidence of progression forat least 4 weeks after CNS- directed treatment, as ascertained by clinicalexamination and brain imaging (MRI or CT scan) during the Screening Period, andthey must be on a stable or decreasing dose of corticosteroids and/oranti-convulsant medications for at least 2 weeks prior to the first dose ofstudy treatment. Participants with history of uncontrolled seizures or LMD arenot eligible.

  • Participants who have not received prior systemic therapy for their locallyadvanced or metastatic NSCLC disease.

  • Prior adjuvant/neoadjuvant treatment for early-stage disease must have beencompleted >6 months prior to the first dose of study treatment. Participantsmay not have received prior adjuvant/neoadjuvant treatment with any EGFRtyrosine kinase inhibitor (TKI).

  1. Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).

  2. Archival tumor tissue available for submission, with minimum quantity sufficient toevaluate EGFRmt status and, where possible, other biomarkers (details provided in alaboratory manual). Participants with insufficient tissue may be eligible followingdiscussion with the Sponsor.

  3. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 17.

  4. Adequate organ function, as defined by the hematologic, renal and hepatic laboratoryvalues.

  5. Women of childbearing potential (WOCBP) must have a negative serum pregnancy testprior to administration of the first dose of study treatment. Female participantsare not considered to be of childbearing potential if they are post-menopausal (nomenses for 12 months without an alternative medical cause) or permanently sterile (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).

  6. Both males and females of reproductive potential must agree to use effective birthcontrol during the study prior to the first dose of study drug and for 1 month afterthe last dose of study treatment.

Exclusion

Exclusion Criteria:

  1. Patient is currently receiving an investigational drug in a clinical trial orparticipating in any other type of medical research judged to be scientifically ormedically incompatible with this study.

  2. Has received any of the following within the specific time frame specified:

  3. Patient has received Zipalertinib (TAS6417/CLN081) at any time

  4. Thoracic radiotherapy ≤28 days or palliative radiation (gamma kniferadiotherapy is allowed) ≤14 days prior to the first dose of study treatment

  5. Anticancer immunotherapy ≤28 days prior to the first dose of study treatment

  6. Major surgery (excluding placement of vascular access) ≤28 days prior to thefirst dose of study treatment.

  7. All prescribed medication, over-the-counter medication, vitamin preparationsand other food supplements, or herbal medications that are strong or moderateCYP3A4 inducers or inhibitors within 7 days prior to first dose of studytreatment

  8. Have any unresolved toxicity of Grade ≥2 from previous anticancer treatment, exceptfor Grade 2 alopecia or skin pigmentation. Participants with other chronic butstable Grade 2 toxicities may be allowed to enroll after agreement between theInvestigator and Sponsor.

  9. Past medical history of interstitial lung disease, treatment-related pneumonitis (any grade), or evidence of clinically active interstitial lung disease.

  10. Impaired cardiac function or clinically significant cardiac disease including any ofthe following:

  11. History of congestive heart failure (CHF) Class III/IV according to the NewYork Heart Association (NYHA) Functional Classification.

  12. Serious cardiac arrhythmias requiring treatment.

  13. Resting corrected QT interval (QTc) >470 msec using Fridericia's formula (QTcF).

  14. Is unable to swallow tablets or has any disease or condition that may significantlyaffect gastrointestinal absorption of zipalertinib (eg, inflammatory bowel disease,malabsorption syndrome, or prior gastric/bowel resection).

  15. History of another primary malignancy ≤2 years prior to the date of first dose ofstudy treatment unless at least one of the following criteria are met:

  16. Adequately treated basal or squamous cell carcinoma of the skin

  17. Cancer of the breast or cervix in situ

  18. Participants with previously treated malignancy if all treatment for thatmalignancy was completed at least 2 years prior to first dose and no evidenceof disease

  19. Participants with concurrent malignancy clinically stable and not requiringtumor-directed treatment

  20. Known history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)that is not controlled with treatment.

  21. History of Coronavirus disease 2019 (COVID-19) infection within 4 weeks prior toenrollment and/or has persistent clinically significant pulmonary symptoms relatedto prior COVID-19 infection.

  22. Active bleeding disorders.

  23. Known hypersensitivity to the ingredients in zipalertinib or any drugs similar instructure or class.

  24. Is pregnant, lactating, or planning to become pregnant.

Study Design

Total Participants: 160
Treatment Group(s): 1
Primary Treatment: TAS6417
Phase: 2
Study Start date:
July 27, 2023
Estimated Completion Date:
August 31, 2026

Study Description

This study will evaluate the safety and efficacy of zipalertinib in participants with locally advanced or metastatic NSCLC harboring EGFR ex20ins mutations or other uncommon/single or compound Epidermal Growth Factor Receptor Proteins Mutations (EGFRmts).

Participants will be enrolled into 1 of the 4 following cohorts:

  • Cohort A ("prior ex20ins treatment") will include participants harboring EGFR ex20ins who have progressed on or after initial treatment with standard platinum-based chemotherapy and prior treatment with an ex20ins agent for their advanced disease (administered together or separately).

  • Cohort B ("first-line") will include participants harboring EGFR ex20ins who have not received prior treatment for advanced or metastatic disease and are not appropriate candidates for first-line doublet platinum-based chemotherapy or have refused first-line doublet platinum-based chemotherapy.

  • Cohort C ("active brain mets") will include participants harboring EGFR ex20ins or other uncommon single or compound EGFRmts and active brain metastases and/or leptomeningeal disease (LMD). Participants may or may not have had prior treatment for advanced disease.

  • Cohort D ("other uncommon EGFRmts") will include participants harboring other non-ex20ins, excluding C797S (uncommon single or compound) EGFRmts who have not received prior systemic therapy for their locally advanced or metastatic NSCLC disease.

Connect with a study center

  • Bankstown-Lidcombe Hospital

    Bankstown, New South Wales 2200
    Australia

    Site Not Available

  • GenesisCare - North Shore

    Saint Leonards, New South Wales 2065
    Australia

    Site Not Available

  • Joondalup Health Campus

    Joondalup, Western Australia 6027
    Australia

    Site Not Available

  • Joondalup Health Campus

    Melbourne,
    Australia

    Site Not Available

  • McGill University Health Centre

    Montréal, Quebec H4A 3J1
    Canada

    Site Not Available

  • William Osler Health System - Brampton Civic Hospital

    Brampton, L6R 3J7
    Canada

    Site Not Available

  • Les Hôpitaux Universitaires de Strasbourg

    Strasbourg cedex, Aslace 67091
    France

    Site Not Available

  • Hôpital Côte De Nacre

    Caen cedex 9, Basse-Normandie 14033
    France

    Site Not Available

  • Institut Curie

    Paris cedex 05, Ile-de-France 75248
    France

    Site Not Available

  • Centre Hospitalier Universitaire Limoges

    Limoges cedex, Limousin 87042
    France

    Site Not Available

  • Centre Hospitalier Universitaire De Nantes - Hôpital Nord Laennec

    Saint-Herblain, Loire-Atlantique 44805
    France

    Site Not Available

  • Hôpital Haut-Lévêque

    Pessac, Nouvelle-Aquitaine 33604
    France

    Site Not Available

  • Institut Sainte Catherine

    Avignon cedex 9, Provence Alpes Cote d'Azure 84918
    France

    Site Not Available

  • Hôpital Nord de Marseille

    Marseille, Provence Alpes Cote d´Azur 13015
    France

    Site Not Available

  • Centre Léon Bérard

    Lyon, Rhone-Alpes 69008
    France

    Site Not Available

  • Gustave Roussy

    Villejuif, Val-de-Marne 94805
    France

    Site Not Available

  • Hôpital Ambroise-Paré

    Boulogne-Billancourt, Île-de-France 92100
    France

    Site Not Available

  • Klinikum Esslingen

    Esslingen, Baden-Wuerttemberg 73730
    Germany

    Site Not Available

  • Asklepios Klinik Altona

    Hamburg, Hamburg (Hansestadt) 22763
    Germany

    Site Not Available

  • Klinikum Kassel

    Kassel, Hassen 34125
    Germany

    Site Not Available

  • Universitätsklinikum Gießen und Marburg - Gießen

    Gießen, Hessen 35392
    Germany

    Site Not Available

  • Pius-Hospital Oldenburg

    Oldenburg, Niedersachsen 26121
    Germany

    Site Not Available

  • Universität zu Köln

    Köln, Nordrhein-Westfalen 50937
    Germany

    Site Not Available

  • Universitatsklinikum Carl Gustav Carus Dresden

    Dresden, SAchsen 01301
    Germany

    Site Not Available

  • LMU Klinikum - Campus Innenstadt

    München, 80337
    Germany

    Site Not Available

  • Universitätsklinikum Regensburg

    Regensburg, 93053
    Germany

    Site Not Available

  • Queen Mary Hospital - Hong Kong

    Pok Fu Lam, Hong Kong Island
    Hong Kong

    Site Not Available

  • Queen Mary Hospital - Hong Kong

    Pok Fu Lam Rd, Hong Kong Island
    Hong Kong

    Site Not Available

  • The Chinese University of Hong Kong

    Sha Tin, New Territories
    Hong Kong

    Site Not Available

  • Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST

    Ravenna, Emilia-romagna 48121
    Italy

    Active - Recruiting

  • Azienda Ospedaliero - Universitaria Careggi

    Firenze, Florence 50134
    Italy

    Site Not Available

  • Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST

    Meldola, Forli-Cesena 47014
    Italy

    Site Not Available

  • Ospedale Degli Infermi di Faenza

    Faenza, Ravenna 48018
    Italy

    Site Not Available

  • Ospedale IUmberto Ii di Lugo

    Lugo, Ravenna 48022
    Italy

    Site Not Available

  • Azienda Ospedaliero - Universitaria San Luigi Gonzaga

    Orbassano, Torino 10043
    Italy

    Site Not Available

  • Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo - Alessandria

    Alessandria, 15121
    Italy

    Site Not Available

  • Azienda Ospedaliero-Universitaria di Bologna - Policlinico Sant Orsola-Malpighi

    Bologna, 40138
    Italy

    Site Not Available

  • Azienda Ospedaliero Universitaria Policlinico Gaspare Rodolico - San Marco

    Catania, 95125
    Italy

    Site Not Available

  • Azienda Socio-Sanitaria Territoriale di Cremona

    Cremona, 26100
    Italy

    Site Not Available

  • Ospedale di Cremona

    Cremona, 26100
    Italy

    Site Not Available

  • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale Policlinico San Martino

    Genova, 16132
    Italy

    Site Not Available

  • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele

    Milan, 20132
    Italy

    Site Not Available

  • Azienda Ospedaliero - Universitaria di Modena

    Modena, 41124
    Italy

    Site Not Available

  • Azienda Ospedaliera Universitaria - Università degli Studi della Campania Luigi Vanvitelli

    Napoli, 80138
    Italy

    Site Not Available

  • Azienda Ospedaliero-Universitaria di Parma

    Parma, 43126
    Italy

    Site Not Available

  • Fondazione IRCCS Policlinico San Matteo

    Pavia, 27100
    Italy

    Site Not Available

  • Azienda Unità Sanitaria Locale - Piacenza

    Piacenza, 29121
    Italy

    Site Not Available

  • Azienda Unità Sanitaria Locale della Romagna

    Ravenna, 48121
    Italy

    Site Not Available

  • Istituto Nazionale Tumori Regina Elena

    Roma, 00144
    Italy

    Site Not Available

  • Aichi Cancer Center

    Nagoya, Aiti 464-8681
    Japan

    Site Not Available

  • Kyushu Cancer Center

    Fukuoka-shi, Hukuoka 811-1395
    Japan

    Site Not Available

  • Sendai Kousei Hospital

    Sendai, Miyagi 980-0873
    Japan

    Site Not Available

  • Kindai University Hospital

    Ōsaka-sayama-Shi, Osaka 589-8511
    Japan

    Site Not Available

  • Shizuoka Cancer Center

    Sunto-gun, Sizuoka 411-8777
    Japan

    Site Not Available

  • National Cancer Center Hospital East

    Kashiwa-shi, Tiba 277-8577
    Japan

    Site Not Available

  • Cancer Institute Hospital of JFCR

    Koto, Tokyo 135-8550
    Japan

    Active - Recruiting

  • Niigata Cancer Center Hospital

    Niigata, 951-8566
    Japan

    Site Not Available

  • Okayama University Hospital

    Okayama, 700-8558
    Japan

    Site Not Available

  • National Cancer Center Hospital

    Tokyo, 104-0045
    Japan

    Site Not Available

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-Do 13620
    Korea, Republic of

    Site Not Available

  • National Cancer Center - Korea

    Goyang-si, Gyeonggi-do 10408
    Korea, Republic of

    Site Not Available

  • Ajou University Hospital

    Suwon-si, Gyeonggi-do 16499
    Korea, Republic of

    Site Not Available

  • Catholic University of Korea Saint Vincent's Hospital

    Suwon-si, Gyeonggi-do 16247
    Korea, Republic of

    Site Not Available

  • Gyeongsang National University Hospital

    Jinju, Gyeongsangnamdo [Kyongsangnam-do] 52727
    Korea, Republic of

    Site Not Available

  • Inha University Hospital

    Incheon, Incheon Gwang'yeogsi [Inch'on-Kwangyokshi] 22332
    Korea, Republic of

    Site Not Available

  • Chonnam National University Hwasun Hospital

    Hwasun, Jeollanam-do 58128
    Korea, Republic of

    Site Not Available

  • Asan Medical Center

    Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi] 05505
    Korea, Republic of

    Site Not Available

  • Korea University Guro Hospital

    Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi] 08308
    Korea, Republic of

    Site Not Available

  • Seoul National University Hospital

    Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi] 03080
    Korea, Republic of

    Site Not Available

  • The Catholic University of Korea - Seoul St. Mary's Hospital

    Soeul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi] 06591
    Korea, Republic of

    Site Not Available

  • Institut Català d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet)

    L'Hospitalet De Llobregat, Barcelona 08908
    Spain

    Site Not Available

  • Complejo Hospitalario Universitario A Coruña

    A Coruña, La Coruña 15006
    Spain

    Site Not Available

  • Hospital Regional Universitario de Málaga - Hospital General

    Málaga, Malaga 29010
    Spain

    Site Not Available

  • Clínica Mi Tres Torres

    Barcelona, 08017
    Spain

    Site Not Available

  • Hospital Clinic de Barcelona

    Barcelona, 08036
    Spain

    Site Not Available

  • Hospital Quirónsalud Barcelona

    Barcelona, 08023
    Spain

    Active - Recruiting

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, 08025
    Spain

    Site Not Available

  • Hospital Universitario de Jaén

    Jaén, 23007
    Spain

    Site Not Available

  • Hospital Universitario 12 de Octubre

    Madrid, 28041
    Spain

    Active - Recruiting

  • Hospital Universitario Fundación Jiménez Díaz

    Madrid, 28040
    Spain

    Site Not Available

  • Hospital Universitario La Paz

    Madrid, 28046
    Spain

    Site Not Available

  • MD Anderson Cancer Center Madrid

    Madrid, 28033
    Spain

    Site Not Available

  • T.C. Saglik Bakanligi Ankara Bilkent Sehi?r Hastanesi?

    Cankaya, Ankara 06800
    Turkey

    Site Not Available

  • Ankara Il Saglik Mudurlugu SBU Gulhane Egitim Ve Arastirma Hastanesi

    Etlik, Ankara 06010
    Turkey

    Site Not Available

  • Dicle Üniversitesi Tip Fakültesi

    Sur, Diyarbakir 21280
    Turkey

    Site Not Available

  • Istinye Üniversite Hastanesi Liv Hospital Bahcesehir

    Esenyurt, Istanbul 34517
    Turkey

    Site Not Available

  • Medical Park Seyhan Hastanesi

    Adana, 01040
    Turkey

    Site Not Available

  • T.C. Saglik Bakanligi Adana Sehir Egitim ve Arastirma Hastanesi

    Adana, 01370
    Turkey

    Site Not Available

  • Hacettepe Üniversitesi Kanser Enstitüsü

    Ankara, 06100
    Turkey

    Site Not Available

  • Memorial Ankara Hastanesi

    Ankara, 6520
    Turkey

    Site Not Available

  • Trakya Üniversitesi Saglik Arastirma ve Uygulama Merkezi

    Edirne, 22030
    Turkey

    Site Not Available

  • Bagcilar Medipol Mega Universite Hastanesi

    Istanbul, 34214
    Turkey

    Site Not Available

  • T.C. Saglik Bakanligi - Istanbul Il Saglik Mudurlugu - Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi

    Istanbul, 34722
    Turkey

    Site Not Available

  • Royal Free London NHS Foundation Trust

    London, England NW3 2QG
    United Kingdom

    Site Not Available

  • The Christie NHS Foundation Trust

    Manchester, England M20 4BX
    United Kingdom

    Site Not Available

  • Nottingham University Hospitals NHS Trust

    Nottingham, England NG5 1PB
    United Kingdom

    Site Not Available

  • Torbay and South Devon NHS Foundation Trust

    Torquay, England TQ2 7AA
    United Kingdom

    Site Not Available

  • The Clatterbridge Cancer Centre NHS Foundation Trust

    Wirral, England CH63 4JY
    United Kingdom

    Site Not Available

  • O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham

    Birmingham, Alabama 35294
    United States

    Site Not Available

  • City of Hope - Duarte (Main Campus)

    Duarte, California 91010
    United States

    Site Not Available

  • City of Hope - Huntington Beach

    Huntington Beach, California 92648
    United States

    Site Not Available

  • City of Hope Orange County Lennar Foundation Cancer Center

    Irvine, California 92618
    United States

    Site Not Available

  • SCRI - Florida Cancer Specialists - East Region Research Office

    West Palm Beach, Florida 33401
    United States

    Site Not Available

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts 02115
    United States

    Site Not Available

  • Comprehensive Cancer Centers of Nevada - Henderson

    Henderson, Nevada 89052
    United States

    Site Not Available

  • Comprehensive Cancer Centers of Nevada - Horizon Ridge Henderson

    Henderson, Nevada 89052
    United States

    Site Not Available

  • Comprehensive Cancer Centers of Nevada - Southeast Henderson - Stephanie

    Henderson, Nevada 89074
    United States

    Site Not Available

  • Comprehensive Cancer Centers of Nevada - Central Valley - Twain

    Las Vegas, Nevada 89169
    United States

    Site Not Available

  • Comprehensive Cancer Centers of Nevada - Northwest

    Las Vegas, Nevada 89128
    United States

    Site Not Available

  • Comprehensive Cancer Centers of Nevada - Southwest

    Las Vegas, Nevada 89148
    United States

    Site Not Available

  • Comprehensive Cancer Centers of Nevada - Summerlin Medical Center II

    Las Vegas, Nevada 89144
    United States

    Site Not Available

  • Memorial Sloan Kettering Cancer Center - Basking Ridge

    Basking Ridge, New Jersey 07920
    United States

    Site Not Available

  • Memorial Sloan Kettering Cancer Center - Monmouth

    Middletown, New Jersey 07748
    United States

    Active - Recruiting

  • Memorial Sloan Kettering Cancer Center - Bergen

    Montvale, New Jersey 07645
    United States

    Site Not Available

  • Memorial Sloan Kettering Cancer Center - Commack

    Commack, New York 11725
    United States

    Site Not Available

  • Memorial Sloan Kettering Cancer Center - Westchester

    Harrison, New York 10604
    United States

    Site Not Available

  • MSK Cancer Center

    Long Island City, New York 11101
    United States

    Active - Recruiting

  • Memorial Sloan Kettering Cancer Center - New York

    New York, New York 10065
    United States

    Site Not Available

  • Memorial Sloan Kettering Cancer Center - Nassau

    Uniondale, New York 11553
    United States

    Site Not Available

  • Gabrail Cancer and Research Center

    Canton, Ohio 44718
    United States

    Site Not Available

  • SCRI - Mark H. Zangmeister Cancer Center

    Columbus, Ohio 43219
    United States

    Site Not Available

  • The Toledo Clinic Cancer Center

    Toledo, Ohio 43623
    United States

    Site Not Available

  • USOR - Alliance Cancer Specialists - Horsham (Abington Hematology Oncology Associates)

    Horsham, Pennsylvania 19044
    United States

    Site Not Available

  • Tennessee Oncology - Nashville - Centennial Clinic - Medical Oncology

    Nashville, Tennessee 37203
    United States

    Site Not Available

  • University of Texas MD Anderson Cancer Center

    Houston, Texas 77030
    United States

    Active - Recruiting

  • Virginia Cancer Specialists - Arlington Office

    Arlington, Virginia 22205
    United States

    Site Not Available

  • Virginia Cancer Specialists - Fairfax Office

    Fairfax, Virginia 22031
    United States

    Site Not Available

  • Virginia Cancer Specialists - Gainesville Office

    Gainesville, Virginia 20155
    United States

    Site Not Available

  • Virginia Cancer Specialists - Reston

    Reston, Virginia 20190
    United States

    Active - Recruiting

  • Froedtert and Medical College of Wisconsin

    Milwaukee, Wisconsin 53226
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.